DM
EUCR

Deerfield Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Deerfield Management’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-999,999
Closed -$10M – 130
2022
Q3 		$10M Hold
999,999
– – 0.2% 81
2022
Q2 		$9.9M Hold
999,999
– – 0.2% 78
2022
Q1 		$9.84M Hold
999,999
– – 0.22% 71
2021
Q4 		$9.76M Buy
+999,999
New +$9.8M 0.2% 86

Other funds holding EUCR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Deerfield Management's EUCR Position: Q4 2022 in Review

Deerfield Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 999,999 shares — an estimated $10M sold.

Deerfield Management first reported a position in EUCR in Q4 2021 and held it in 4 quarters. The position peaked at $10M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

  • Deerfield Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Deerfield Management sold 999,999 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $10M.
  • Deerfield Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 4 quarters.
  • Deerfield Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $10M in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.